235 related articles for article (PubMed ID: 26950049)
1. Genetic Predictors of Azathioprine Toxicity and Clinical Response in Patients with Inflammatory Bowel Disease.
Al-Judaibi B; Schwarz UI; Huda N; Dresser GK; Gregor JC; Ponich T; Chande N; Mosli M; Kim RB
J Popul Ther Clin Pharmacol; 2016; 23(1):e26-36. PubMed ID: 26950049
[TBL] [Abstract][Full Text] [Related]
2. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression.
Zelinkova Z; Derijks LJ; Stokkers PC; Vogels EW; van Kampen AH; Curvers WL; Cohn D; van Deventer SJ; Hommes DW
Clin Gastroenterol Hepatol; 2006 Jan; 4(1):44-9. PubMed ID: 16431304
[TBL] [Abstract][Full Text] [Related]
3. TPMT and ITPA genetic variants in Lithuanian inflammatory bowel disease patients: Prevalence and azathioprine-related side effects.
Steponaitiene R; Kupcinskas J; Survilaite S; Varkalaite G; Jonaitis L; Kiudelis G; Denapiene G; Valantinas J; Skieceviciene J; Kupcinskas L
Adv Med Sci; 2016 Mar; 61(1):135-40. PubMed ID: 26674571
[TBL] [Abstract][Full Text] [Related]
4. A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine.
Zabala-Fernández W; Barreiro-de Acosta M; Echarri A; Carpio D; Lorenzo A; Castro J; Martínez-Ares D; Pereira S; Martin-Granizo I; Corton M; Carracedo A; Barros F
J Gastrointestin Liver Dis; 2011 Sep; 20(3):247-53. PubMed ID: 21961091
[TBL] [Abstract][Full Text] [Related]
5. Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease.
Stocco G; Martelossi S; Barabino A; Decorti G; Bartoli F; Montico M; Gotti A; Ventura A
Inflamm Bowel Dis; 2007 Jan; 13(1):57-64. PubMed ID: 17206640
[TBL] [Abstract][Full Text] [Related]
6. Deletion of glutathione-s-transferase m1 reduces azathioprine metabolite concentrations in young patients with inflammatory bowel disease.
Stocco G; Cuzzoni E; De Iudicibus S; Franca R; Favretto D; Malusà N; Londero M; Cont G; Bartoli F; Martelossi S; Ventura A; Decorti G
J Clin Gastroenterol; 2014 Jan; 48(1):43-51. PubMed ID: 23787247
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of thiopurine therapy in paediatric IBD patients.
De Ridder L; Van Dieren JM; Van Deventer HJ; Stokkers PC; Van der Woude JC; Van Vuuren AJ; Benninga MA; Escher JC; Hommes DW
Aliment Pharmacol Ther; 2006 Apr; 23(8):1137-41. PubMed ID: 16611274
[TBL] [Abstract][Full Text] [Related]
8. Comparison of
Wang HH; He Y; Wang HX; Liao CL; Peng Y; Tao LJ; Zhang W; Yang HX
World J Gastroenterol; 2018 Feb; 24(8):941-948. PubMed ID: 29491687
[TBL] [Abstract][Full Text] [Related]
9. The impact of thiopurine-S-methyltransferase genotype on the adverse drug reactions to azathioprine in patients with inflammatory bowel diseases.
Hlavaty T; Batovsky M; Balakova D; Pav I; Celec P; Gregus M; Zakuciova M; Hlista M; Horakova M; Desatova B; Koller T; Toth J; Kadasi L; Huorka M;
Bratisl Lek Listy; 2013; 114(4):199-205. PubMed ID: 23514552
[TBL] [Abstract][Full Text] [Related]
10. Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events.
Sayani FA; Prosser C; Bailey RJ; Jacobs P; Fedorak RN
Can J Gastroenterol; 2005 Mar; 19(3):147-51. PubMed ID: 15776134
[TBL] [Abstract][Full Text] [Related]
11. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
Cao Q; Zhu Q; Shang Y; Gao M; Si J
Digestion; 2009; 79(1):58-63. PubMed ID: 19252404
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease.
Daperno M; Sostegni R; Canaparo R; Serpe L; Lavagna A; Crocellà L; Castagno F; Vernetto A; Rigazio C; Ercole E; D'Antico S; Pera A; Zara G; Rocca R
Aliment Pharmacol Ther; 2009 Oct; 30(8):843-53. PubMed ID: 19650826
[TBL] [Abstract][Full Text] [Related]
13. Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients.
Gazouli M; Pachoula I; Panayotou I; Mantzaris G; Syriopoulou VP; Goutas N; Vlachodimitropoulos D; Anagnou NP; Roma-Giannikou E
J Clin Pharm Ther; 2010 Feb; 35(1):93-7. PubMed ID: 20175817
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients.
Carvalho AT; Esberard BC; Fróes RS; Rapozo DC; Grinman AB; Simão TA; Santos JC; Carneiro AJ; Ribeiro-Pinto LF; de Souza HS
World J Gastroenterol; 2014 Mar; 20(12):3327-34. PubMed ID: 24696613
[TBL] [Abstract][Full Text] [Related]
15. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase).
Marinaki AM; Ansari A; Duley JA; Arenas M; Sumi S; Lewis CM; Shobowale-Bakre el-M; Escuredo E; Fairbanks LD; Sanderson JD
Pharmacogenetics; 2004 Mar; 14(3):181-7. PubMed ID: 15167706
[TBL] [Abstract][Full Text] [Related]
16. TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease.
Stocco G; Martelossi S; Barabino A; Fontana M; Lionetti P; Decorti G; Malusà N; Bartoli F; Fezzi M; Giraldi T; Ventura A
Dig Liver Dis; 2005 Dec; 37(12):940-5. PubMed ID: 16202677
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.
Ansari A; Arenas M; Greenfield SM; Morris D; Lindsay J; Gilshenan K; Smith M; Lewis C; Marinaki A; Duley J; Sanderson J
Aliment Pharmacol Ther; 2008 Oct; 28(8):973-83. PubMed ID: 18616518
[TBL] [Abstract][Full Text] [Related]
18. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
[TBL] [Abstract][Full Text] [Related]
19. ITPA polymorphisms do not predict additional risk beyond TPMT and NUDT15 for thiopurine-induced cytopenia in inflammatory bowel disease.
Jena A; Grover N; Bhatia P; Singh M; Lad D; Prasad KK; Singh H; Dutta U; Sharma V
Rev Gastroenterol Mex (Engl Ed); 2024; 89(1):25-30. PubMed ID: 36707393
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for serious adverse effects of thiopurines in patients with Crohn's disease.
Mazor Y; Koifman E; Elkin H; Chowers Y; Krivoy N; Karban A; Efrati E
Curr Drug Saf; 2013 Jul; 8(3):181-5. PubMed ID: 23845145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
